Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Qiu, Tian ^a   Guo, Huiqin ^a   Zhao, Huan ^a   Wang, Luhua ^a   Zhang, Zhihui ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR PROTEIN;

ADENOCARCINOMA; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; LUNG NEOPLASMS; MALE; MUTATION; PATHOLOGY;

ADENOCARCINOMA; BIOPSY, FINE-NEEDLE; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM PROTEINS;

EID: 84931261518     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11317     Document Type: Article

References (22)

1. Parkin, D. M., Pisani, P., Ferlay, J. Global cancer statistics. CA Cancer J Clin 49, 33-64 (1999).
2. Parkin, D. M., Bray, F., Ferlay, J. , Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108 (2005).
3. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90 (2011).
4. Schiller, J. H. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346, 92-98 (2002).
5. Leighl, N. B. et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol 32, 3673-3679 (2014).
6. Kancha, R. K., von Bubnoff, N., Peschel, C. , Duyster, J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 15, 460-467 (2009).
7. Shepherd, F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353, 123-132 (2005).
8. Natale, R. B. et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-smallcell lung cancer. J Clin Oncol 29, 1059-1066 (2011).
9. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362, 2380-2388 (2010).
10. Peng, L., Song, Z. G. , Jiao, S. C. Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations. Sci Rep 4, 6104 (2014).
11. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139 (2004).
12. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
13. Fassina, A. et al. Fine needle aspiration of non-small cell lung cancer: current state and future perspective. Cytopathology 23, 213-219 (2012).
14. Metzker, M. L. Sequencing technologies-the next generation. Nat Rev Genet 11, 31-46 (2010).
15. Han, J. Y. et al. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Lung Cancer 85, 161-167 (2014).
16. Ross, J. S. et al. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol 67, 772-776 (2014).
17. Lozano, M. D. et al. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes. Oncologist 16, 877-885 (2011).
18. Stigt, J. A. et al. Comparison of EUS-guided fine needle aspiration and integrated PET-CT in restaging after treatment for locally advanced non-small cell lung cancer. Lung Cancer 66, 198-204 (2009).
19. Gu, P. et al. Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. Eur J Cancer 45, 1389-1396 (2009).
20. Gazdar, A. F. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 361, 1018-1020 (2009).
21. Ellison, G. et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 66, 79-89 (2013).
22. Kanagal-Shamanna, R. et al. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol 27, 314-327 (2014).